Cyclophosphamide: ovarian and other toxicities

Wallace D. A critical appraisal of the use of cyclophosphamide in lupus nephritis. ACR Annual Scientific Meeting, Minneapolis, MN, October 1994.

Hadler H. Is aggressive therapy of lupus nephritis beneficial? ACR Annual Scientific Meeting, Minneapolis, MN, October 1994.

Boumpas DT et al. Severe lupus nephritis: controlled trial of pulse methylprednisolone versus two different regimens of pulse cyclophosphamide. Lancet 1992; 340: 741-744.

Austin HA et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.

McInnes PM et al. The economic impact of treatment of severe lupus nephritis with prednisolone and cytotoxic drugs. Arthritis Rheum 1994; 37: 1000-1006.

Klippel JH Is aggressive therapy effective for lupus? In: Sergent JS , Panush RS (eds). Controversies in Clinical Rheumatology. Rheumatic Disease Clinics of North America, Philadelphia, WB Saunders , 1993, pp. 249-261.

Kattwinkel N. , Cook L. , Agnello V. Overwhelming fatal infection in a young woman after intravenous cyclophosphamide therapy for lupus nephritis. J Rheumatol 1991; 18: 79-81.

Thrasher JB , Miller GJ , Wettlaufer JN Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis . J Urol 1990; 143: 119-121.

Vasquez S. et al. Acute non-lymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. J Rheumatol 1992; 19: 1625-1627.

Boumpas DT et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide. Ann Intern Med 1993; 119: 366-369.

Vose JM et al. Mesna compared with continuous bladder irngation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial. J Clin Oncol 1993; 11: 1306-1310.

Pando JA et al. Risks of malignancy in patients with lupus nephritis treated with bolus cyclophosphamide. Arthritis Rheum 1994; 37: S179.

Krcuscr ED et al. Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Ann Oncol 1992; 3(Suppl 4): 105-110.

Wang CL , Wang F. , Bosco JJ Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus . Lupus 1995; 4: 11-14.

Plowchalk DR , Mattison DR Phosphoramide mustard is responsible for the ovarian toxicity of cyclophosphamide. Toxicol Appl Pharmacol 1991; 107: 472-481.

Nicosia SV , Matus-Ridley M. , Meadows AT Gonadal effects of cancer therapy in girls. Cancer 1985; 55: 2364-2372.

Jarrell JF et al. The short-term reproductive toxicity of cyclophosphamide in the female rat. Reprod Toxicol 1991; 5: 481-485.

Houssiau FA et al. Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study. Lupus 1991; 1: 31-35.

Pando JA et al. Rates of renal remission and relapse in patients with lupus nephritis treated with bolus cyclophosphamide. Arthritis Rheum 1994; 37: S179.

Ataya KM et al. A luteinizing-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 1985; 45: 3651-3656.

Falkson CI , Falkson HC , Falkson G. Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancer. Eur J Cancer 1991; 27: 1208-1211.

Montz FJ , Wolff AJ , Gambone JC Gonadal protection and fecundity rates in cyclophosphamide-treated rats. Cancer Res 1991; 51: 2124-2126.

Chapman R. , Sutcliffe S. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood 1981; 58: 849-851.